Manuscript version: Author’s Accepted Manuscript
The version presented in WRAP is the author’s accepted manuscript and may differ from the published version or Version of Record.

Persistent WRAP URL:
http://wrap.warwick.ac.uk/125487

How to cite:
Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

Copyright and reuse:
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher’s statement:
Please refer to the repository item page, publisher’s statement section, for further information.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk.
Packages of Sodium (Salt) sold for consumption and salt dispensers should be required to have a front of package health warning label. A position statement of the World Hypertension League, national and international health and scientific organizations.

Short title: Warning labels on packages of sodium (salt)

Norm RC Campbell, MD (Corresponding Author)
Jacqui Webster, PhD
Adriana Blanco-Metzler, MSc
Feng J He, PhD
Monique Tan, MSc
Graham A MacGregor, MD
Francesco P Cappuccio, MD MSc DSc FRCP FFPH FBHS FESC FAHA
JoAnne Arcand PhD, RD
Kathy Trieu, PhD
Clare Farrand, MSc
Alexandra Jones, LLM
Paul K Whelton, MB, MD, MSc
Xin-Hua Zhang, MD, PhD

Norm RC Campbell MD. Department of Medicine, Physiology and Pharmacology and Community Health Sciences, O’Brien Institute for Public Health and Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada, Tel: (403) 210-7961, Fax: (403) 210-9837, email: ncampbel@ucalgary.ca

Jacqui Webster, PhD. The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. email: jwebster@georgeinstitute.org.au

Adriana Blanco-Metzler MSc. Unit of Health and Nutrition, Costa Rican Institute of Research and Teaching in Nutrition and Health, Tres Rios, Costa Rica, Tel (506) 2279-9911, Fax (506) 2279-5546, email: ablanco@inciensa.sa.cr

Feng J He PhD. Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London EC1M 6BQ, UK. Tel: 44 20 7882 6266, Fax: 44 20 7882 6270, email: f.he@qmul.ac.uk

Monique Tan MSc. Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London EC1M 6BQ, UK. Tel: 44 20 7882 6266, Fax: 44 20 7882 6270, email: m.tan@qmul.ac.uk

Graham A MacGregor MD. Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London EC1M 6BQ, UK. Tel: 44 20 7882 6217, Fax: 44 20 7882 6270, email: g.macgregor@qmul.ac.uk

Francesco P Cappuccio MD MSc DSc FRCP FFPH FBHS FESC FAHA, Cephalon Professor of Cardiovascular Medicine & Epidemiology. Division of Health Sciences (Mental Health & Wellbeing), Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK, email: f.p.cappuccio@warwick.ac.uk

JoAnne Arcand PhD, RD. Ontario Tech University (University of Ontario Institute of Technology), Oshawa, Ontario, Canada. email: joanne.arcand@uoit.ca

Kathy Trieu PhD. The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. Tel: +61 2 8052 4645, email: ktrieu@georgeinstitute.org.au
Clare Farrand MSc. The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. email: cfarrand@georgeinstitute.org.au

Alexandra Jones LLM (Global Health Law), The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. Tel: +61 2 8052 4629, email: ajones@georgeinstitute.org.au

Paul K. Whelton MB, MD, MSc. Show Chwan Professor of Global Public Health, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, Tulane University of Medicine, email: pkwhelton@gmail.com

Xin-Hua Zhang MD, PhD Beijing Hypertension League Institute, Beijing, China email: zhang_xh@hotmail.com.au

Conflicts of Interest: NRCC was a paid consultant to the Novartis Foundation (2016-2017) to support their program to improve hypertension control in low to middle income countries which includes travel support for site visits and a contract to develop a survey. NRCC has provided paid consultative advice on accurate blood pressure assessment to Midway Corporation (2017) and is an unpaid member of World Action on Salt and Health (WASH). JW is Director of the World Health Organization Collaborating Centre on Population Salt Reduction. She is supported by an Australian National Heart Foundation Future Leaders Fellowship and receives funding from WHO, the Australian National Health and Medical Research Council, Victorian Health Promotion Foundation and Vital Strategies for work on salt reduction. GAM is Chairman of Blood Pressure UK (BPUK), Chairman of Consensus Action on Salt & Health (CASH), WASH and Action on Sugar. BPUK, CASH, WASH and Action on Sugar are non-profit charitable organizations. GAM does not receive any financial support from any of these organizations. FC is President and Trustee, British and Irish Hypertension Society; World Health Organization Scientific Advisor; Member of CASH and WASH. FJH is an unpaid member of CASH and WASH. MT, CF, KT JW, AJ, PW and XHZ have no conflicts of interest to disclose.

Position statement: Commercially sold or provided (e.g. in restaurants) packages or containers of sodium chloride (salt) intended for consumption and salt dispensers should be required to have a front of package health warning label. The warning label should be clearly visible, easily readable, indicate that consumption of excess sodium (salt) is a health risk, and recommend that people use less sodium (salt).

Dietary risks in aggregate are the leading risk for death globally. Amongst dietary risks, high dietary sodium (salt) is the leading risk\(^1\). Globally, excess dietary sodium is estimated to have caused over 3 million deaths and over 70 million disability-adjusted life-years (DALYS) in 2017\(^{1,2}\). High dietary sodium is predominantly a risk as a result of increasing blood pressure (the leading single risk for death globally) but is also a probable pro carcinogen for gastric cancer, directly causes cardiovascular and renal damage independent of blood pressure and is associated with several other diseases\(^{1,3-11}\). The recent National Academy of Medicine review of the evidence for dietary sodium consumption in United States and Canada concluded that excess dietary sodium increases blood pressure, that elevated blood pressure causes cardiovascular disease (CVD), and that there is moderately strong evidence that high dietary sodium directly increases total mortality and cardiovascular events\(^12\). In addition, the World Health Organization (WHO) reported that increased dietary sodium increases blood pressure and is associated with CVD\(^13\). Multiple other diseases have associations and biologically sound pathophysiological mechanisms for sodium causing harm, but clinical evidence is not substantive enough to prove causality\(^3\). In addition, acute ingestion of sodium chloride (salt) in the range of 17 g or more in an adult, and 12.5 g or more in an infant can cause seizures, coma and death. Although ingestions of large quantities of sodium are very distasteful and believed to be infrequent, both accidental and intentional deaths do occur\(^{12,14}\).

Reducing excess dietary sodium is a global target of the WHO endorsed by the World Health Assembly, and many countries have started to reduce dietary sodium using a variety of public health interventions\(^15\). The WHO created the SHAKE package to guide countries on policies to reduce dietary sodium\(^16\). In most
countries where most foods consumed are highly processed, the major source of sodium is from processed foods (i.e. hidden sodium) with about 10% coming from sodium added in cooking and at the table (i.e. discretionary sodium)\(^\text{16}\). Although most countries require the amount of sodium to be indicated on labels in processed foods (i.e. nutrition fact panels (NFP)), these labels are difficult for consumers to interpret and do not warn of any risks from consumption\(^\text{17}\). In general, NFP do not indicate if a product is high intermediate or low in sodium. A few other countries such as the United Kingdom have voluntary front of package warning labels for foods high in sodium. Several countries (e.g. Finland, Israel, Iran, Chile, Uruguay, Ecuador, Peru), where sodium in processed foods is the major source, require warning labels on processed foods high in sodium and other countries are considering such labels\(^\text{18}\). Front-of-pack labelling of this kind to reduce sodium intake is recommended by WHO as a ‘best buy’ for NCD prevention\(^\text{19}\). These labels are applicable to foods but not to packages of salt where the only content is sodium chloride.

In much of the world, the major source of sodium is that added as table salt in cooking and at the table\(^\text{16,20}\). Some countries have banned restaurants from pung salt containers at tables to reduce spontaneous addition of sodium to foods and increase awareness of the dangers of high-sodium diets (e.g. Argentina, Uruguay, Mexico City). To our knowledge, no country has required actual packages and containers of sodium chloride (salt) to have warning labels.

Warning labels on packages of sodium chloride (see text box for an example) may have several potential benefits. Firstly, it would increase awareness of the dangers of high-sodium diets by people purchasing sodium and a reminder of the dangers by people seeing the containers at stores or in the home. Secondly, stores that sell sodium chloride may display sodium less prominently. Thirdly, and most importantly, it could lead to a reduction in sodium consumption. A randomized controlled trial found that having patients with hypertension place a warning label on salt shakers at home reduced sodium consumption very substantially\(^\text{21}\). To have maximum impact a warning label should also be considered for other major discretionary sources of dietary sodium (e.g. soya sauce, fish sauce, bouillon cubes) where sodium is the major component of the product. Low sodium salts (with partial replacement of sodium by potassium and potentially magnesium) should also have a label that promotes use to help reduce dietary sodium but also a warning to reduce consumption and for people with kidney disease or taking antihypertensive or cardiac drugs to seek medical advice before using (to prevent hyperkalemia).

Efforts to reduce excess sodium from discretionary and processed food sources are compatible with the programs to prevent iodine deficiency disorders that use iodized sodium chloride. WHO has recommends coordination of population surveys of dietary sodium and iodine and to adjust the iodine content of sodium chloride based on changes in sodium intake\(^\text{22,23}\).

| Too much sodium in the diet causes high blood pressure and increases risk of stomach cancer, stroke, heart disease and kidney disease. Limit your use. |

This position statement requests governments require health warnings on packages of sodium chloride (salt) sold for consumption and sodium dispensers. The warning label should be clearly visible and easily readable, indicate that consumption of excess sodium is a health risk, and advise consumers to use less sodium. A sample warning label is provided in the text box below.

The following organizations support the position. World Hypertension League, Resolve to Save Lives, World Health Organization Collaborating Centre on Salt Reduction, The George Institute for Global Health, World Action on Salt and Health (WASH), Consensus Action on Salt and Health (CASH), World Health Organization Collaborating Centre for Nutrition, University of Warwick, Hypertension Canada, and the British and Irish Hypertension Society.

Acknowledgement: The authors thanks Michael F. Jacobson, Ph.D. for providing comments on drafts.


